Transparent discussion of the regulatory framework, including the need for a valid prescription and the limits of insurance rebates
Table 2 Overview of GLP-1 receptor agonists (GLP-1RAs) approved by the EMA and/or FDA, with year of authorization and main therapeutic indications
Wutthinan, representing BSL, attended ASLS Bangkok 2025 to bring back knowledge and design treatment approaches that help improve skin health as we age when the skin becomes thinner, drier, uneven in tone, slower to recover, and more prone to wrinkles
AMCP Nexus in focus: Exploring Primes GLP-1 research in depth Ben Urick, senior director of health outcomes, and Landon Marshall, health outcomes research principal, share more about their educational session and research poster on GLP-1s Prior to the release of Prime Therapeutics (Prime) latest cost-of-care data from its ongoing real-world research on glucagon-like peptide-1 (GLP-1) agonist drugs, Prime researchers presented findings from the Year-2 adherence and persistence study as a research poster and an education session at Academy of Managed Care Pharmacy (AMCP) Nexus 2024 in Las Vegas, Nevada
Eli Lilly has adopted a pricing strategy that undercuts Novo Nordisk, offering Zepbound at a lower price for uninsured patients, with some paying as little as $399 per month
Great flavor with all that we have tried* Was this helpful
